Upload
tali-kaplan
View
216
Download
3
Embed Size (px)
DESCRIPTION
הרצאה של פרופ' אנמיקה ארטסמה-רוס במסגרת יום המחלות הנדירות 2012
Citation preview
Exon skipping for DMDAnnemieke Aartsma‐Rus
February 29 2012
Annemieke Aartsma-RusDepartment of Human Genetics 2
Duchenne Muscular Dystrophy (DMD)
Annemieke Aartsma-RusDepartment of Human Genetics 3
Becker Muscular Dystrophy (BMD)
Age
Clin
ical
sym
ptom
s B
MD
Genes and proteins
Annemieke Aartsma-Rus
•• ProteinsProteins building building blocksblocks of of ourour bodybody
•• GenesGenes containcontain blueprintblueprint forfor proteinsproteins
•• MistakeMistake in gene in gene mistakemistake in in proteinprotein
•• GenesGenes have a volume switch have a volume switch
OnlyOnly onon in in necessarynecessary tissuetissue
•• Dystrophin Dystrophin proteinprotein has has functionfunction in in musclemuscle
•• MistakeMistake in dystrophin in dystrophin musclemuscle problemsproblems
Muscles
Annemieke Aartsma-Rus
•• 3030‐‐40% of 40% of ourour body body consistsconsists of of musclemuscle
•• MusclesMuscles cancan growgrow biggerbigger and smallerand smaller
•• MusclesMuscles useuse lot of lot of energyenergy
•• OnlyOnly maintainedmaintained whenwhen neededneeded
•• MusclesMuscles damageddamaged afterafter excessiveexcessive exerciseexercise
•• MusclesMuscles veryvery efficientefficient at at repairingrepairing damagedamage
BiggerBigger whenwhen neededneeded
Muscles
Annemieke Aartsma-Rus
Muscle fibers
Annemieke Aartsma-Rus
SkeletonSkeleton
Connective tissueConnective tissue
Dystrophin
Annemieke Aartsma-Rus
DystrophinDystrophin
Genes and proteins
Annemieke Aartsma-Rus
•• ProteinsProteins building building blocksblocks of of ourour bodybody
•• GenesGenes containcontain blueprintblueprint forfor proteinsproteins
•• GenesGenes consistconsist of DNAof DNA
•• CellCell cancan translate DNA code translate DNA code intointo proteinprotein
Gene Protein
Annemieke Aartsma‐Rus
DNA
Protein factory
Temporary gene copy (RNA)
Cell nucleus
Cell body(cytoplasm)
Dystrophin gene
Annemieke Aartsma-Rus
Splicing
Annemieke Aartsma-Rus
Exons Introns1
35
6
7 Gene (DNA)
RNA copy (pre mRNA)
messenger RNA
1 - - - - - - - - - 79
dystrophin protein
Splicing
2
4
3 4 5 6 71 21 2 3 4 5 6 7 8
Duchenne: reading frame disrupted
Annemieke Aartsma-Rus
Duchenne: reading frame disrupted
Annemieke Aartsma-Rus
Protein translation stops prematurelyProtein translation stops prematurely
Dystrophin not functionalDystrophin not functional
Exon 46 Exon 47 Exon 51 Exon 52?
Becker: reading frame maintained
Annemieke Aartsma-Rus
Becker: reading frame maintained
Annemieke Aartsma-Rus
Protein translation continuesProtein translation continues
Dystrophin partly functionalDystrophin partly functionalLess damageLess damage
Exon 46 Exon 47 Exon 52 Exon 53
Exon skipping: restore reading frame
Annemieke Aartsma-Rus
Exon 51 skipping (del exon 48Exon 51 skipping (del exon 48‐‐50)50)
AnnemiekeAnnemieke AartsmaAartsma‐‐RusRus
52524747
525251514747
MM NTNT 5151 ‐‐RTRT HCHC0h0h 4h4h 8h8h 16h16h 24h24h 48h48h
NT 48 post transfection
MANDYS1 DYS2MANDYS1
Aartsma‐Rus HumMolGen 2003 12: 907‐14
Deletion exon 45‐55
Annemieke Aartsma-Rus
‐AON
+AON +AON
Exon 44 skipping
Annemieke Aartsma‐Rus
‐AON
+AON +AON
MM NTNT 4444 ‐‐RTRT
44444343 5555
55554343
NTNT HC(1:10)HC(1:10)2d2d 4d4d 7d7d
NT
MANDYS1 DYS2
48 hours post transfection
MANDYS1
Double exon skipping
Annemieke Aartsma-Rus
Double Exon Skipping
Annemieke Aartsma-Rus
MM NTNT 45 &
45 &
5151 ‐‐ RTRT
4444 5252
4444 4545 5151 52524444 4545 5252
NTNT 2d2d 3d3d HCHC
Not Treated 48 uur post transfection
Aartsma‐Rus AmJHumGen 2004, 74: 83‐91
Mdxmouse
Annemieke Aartsma-Rus
•• NaturalNatural mousemouse modelmodel
•• DisruptingDisrupting mutationmutation exon 23exon 23
•• Dystrophin Dystrophin deficiencydeficiency
•• MuscleMuscle functionfunction impairedimpaired
•• LessLess severesevere diseasedisease thanthan humanshumans
•• Exon 23 Exon 23 skippingskipping cancan restorerestore geneticgenetic code, code, dystrophin and dystrophin and leadsleads to to functionalfunctional improvementimprovementafterafter intramuscularintramuscular injectioninjection of AONsof AONs
Exon skipping
Annemieke Aartsma-Rus Alter et al. Nat Med 2006, 12: 175‐7
•• Exon Exon skippingskipping and dystrophin and dystrophin restorationrestorationconfirmedconfirmed in in patientpatient‐‐derivedderived cellscells ((deletionsdeletions, , duplicationsduplications, , smallsmall mutationsmutations))
•• Exon Exon skippingskipping, dystrophin , dystrophin restorationrestoration and and musclemusclefunctionfunction improvementimprovement confirmedconfirmed in in mdxmdx mousemousemodel and GRMD model and GRMD dogsdogs ((locallocal and and systemicsystemic!)!)
Applicability
Annemieke Aartsma-Rus Aartsma‐Rus Hum Mutat 2009, 30:293‐9
hotspot
AON chemistry
Annemieke Aartsma-Rus
•• TwoTwo different different chemistrieschemistries developeddeveloped furtherfurther
•• ProsensaProsensa: 2: 2’’‐‐OO‐‐methylmethyl phosphorothioatephosphorothioate
•• AVIAVI‐‐BiopharmaBiopharma: : phosphorodiamidatephosphorodiamidate morpholinomorpholinooligomersoligomers
•• TargetingTargeting exon 51exon 51
First clinical trial – set up
Annemieke Aartsma-Rus
Set upSet up
•• Single Single dosedose, single center , single center studystudy
•• 4 4 prepre‐‐screenedscreened DMD DMD patientspatients agedaged 88‐‐1616
•• Single IM Single IM injectioninjection PRO051 in PRO051 in shinshin musclemuscle
•• BiopsyBiopsy 4 weeks 4 weeks afterafter injectioninjection
•• Exon Exon skipskip? Dystrophin? Safe?? Dystrophin? Safe?
Pre‐screening Baseline Assessment Treatment Follow‐up Safety & Efficacy Assessment
Day ‐60 to ‐7 Day 0 Day 0 Day 1 to 28 Day 28 to 35
First clinical trial – pre‐screening
Annemieke Aartsma-Rus
First clinical trial – analysis RNA
Annemieke Aartsma-Rus
Annemieke Aartsma-Rus
Department of Human Genetics 30
Annemieke Aartsma-Rus
Department of Human Genetics 31Pt.3120 fibers
Pt.2725 fibers
Dystrophin quantification
Annemieke Aartsma-Rus
Second intramuscular trial (AVI)
Annemieke Aartsma-Rus Kinali Lancet Neurol 2009, 8: 918‐28
•• TwoTwo doses doses testedtested (0.09 and 0.9 mg)(0.09 and 0.9 mg)
•• EDB EDB musclemuscle
•• Exon Exon skipskip in all dosesin all doses
•• Dystrophin Dystrophin restorationrestoration onlyonly forfor high high dosedose
Intramuscular trials
Annemieke Aartsma-Rus
•• Exon Exon skippingskipping observedobserved in all in all patientspatients
•• No No toxictoxic effectseffects observedobserved!!
•• Dystrophin Dystrophin levelslevels veryvery comparablecomparable
1717‐‐35% 35% vsvs 2222‐‐32%32%
•• NumberNumber of dystrophin of dystrophin positivepositive cellscells comparablecomparable
6464‐‐97% 97% vsvs 4444‐‐79%79%
•• SystemicSystemic treatmenttreatment neededneeded
Systemic treatment
Annemieke Aartsma-Rus
WT Mice
Mdx Mice
AON levels in muscle and Liver Exon 23 Skipping
Gastrocn.
Systemic treatment
Annemieke Aartsma-Rus
AON Tissue Levels(ug/g)
Systemic treatment
Annemieke Aartsma-Rus
TibialisTibialis AnteriorAnterior
02468
10121416
25 mg/kg 50 mg/kg 100 mg/kg
Dose
% e
xon
23 s
kipp
ing
Tissue Tissue levelslevels RNARNA
0
5
10
15
20
25
25 mg/kg 50 mg/kg 100 mg/kg
Dose
Tiss
ue le
vels
(ug/
g)
02
468
1012
1416
25 mg/kg 50 mg/kg 100 mg/kg
Dose
Dys
trop
hin
%
8 weeks4 weeks
ProteinProtein
SimilarSimilar resultsresults forfor all all skeletalskeletal musclesmusclesHeartHeart lowerlower exon exon skipskip and and proteinprotein levelslevels
Systemic trial 2OMePS (GSK/Prosensa)
Annemieke Aartsma-Rus
GSK2402968 GSK2402968 (0.5, 2, 4 & 6 mg/kg)(0.5, 2, 4 & 6 mg/kg)
•• SubcutaneousSubcutaneous injectionsinjections (abdomen)(abdomen)•• WeeklyWeekly forfor 5 weeks5 weeks•• 3 3 patientspatients per per groupgroup•• BiopsyBiopsy taken 1 taken 1 monthmonth afterafter last last injectioninjection•• No No severesevere sideside effectseffects reportedreported
Open label Open label extensionextension studystudy initiatedinitiated•• All All patientspatients receivereceive 6 mg/kg/week 6 mg/kg/week subcutaneoussubcutaneous
Systemic trial 2OMePS (GSK/Prosensa)
Annemieke Aartsma-Rus
DosePre‐Treatment
*Revertant Fiber
*
Dystrophin (ManDys 106)
Goemans et al, NEJM 2011, 364: 1513‐22
Systemic trial 2OMePS (GSK/Prosensa)
Annemieke Aartsma-Rus Goemans et al, NEJM 2011, 364: 1513‐22
Systemic trial 2OMePS (GSK/Prosensa)
Annemieke Aartsma-Rus
•• Dystrophin Dystrophin restorationrestoration observedobserved in 10/12 in 10/12 patientspatients
•• 6060‐‐100% 100% musclemuscle fibers dystrophin fibers dystrophin positivepositive
•• Dystrophin Dystrophin levelslevels up to 15.6% of up to 15.6% of controlcontrol
•• DoseDose dependentdependent increaseincrease of dystrophin of dystrophin levelslevels
•• Open label Open label extensionextension studystudy initiatedinitiated
•• All All patientspatients enrolledenrolled
•• WeeklyWeekly treatmenttreatment forfor 90+ weeks 90+ weeks
Goemans et al, NEJM 2011, 364: 1513‐22
Systemic trial MDEX/AVI
Annemieke Aartsma-Rus
AVIAVI‐‐4658 4658 (0.5, 1, 2, 4, 10 & 20 mg/kg)(0.5, 1, 2, 4, 10 & 20 mg/kg)
•• IntravenousIntravenous infusionsinfusions
•• WeeklyWeekly forfor 12 weeks12 weeks
•• 22‐‐4 4 patientspatients per per groupgroup ((totaltotal 19)19)
•• BiopsiesBiopsies
•• BeforeBefore treatmenttreatment
•• 2 weeks 2 weeks afterafter last last injectioninjection
•• No No severesevere sideside effectseffects reportedreported
Cirak et al, Lancet 2011, 378: 595‐605
Systemic trials MDEX/AVI
Annemieke Aartsma-Rus
•• ClearClear dystrophin in 7/19 dystrophin in 7/19 patientspatients
•• 77‐‐10% of 10% of controlcontrol prepre‐‐treatmenttreatment
•• 1111‐‐22% of 22% of controlcontrol postpost‐‐treatmenttreatment
•• 3 3 goodgood respondersresponders (2, 10 & 20 mg/kg (2, 10 & 20 mg/kg groupgroup))
•• Up to 55% dystrophin Up to 55% dystrophin positivepositive fibersfibers
•• Up to 18% dystrophin (Western Up to 18% dystrophin (Western blotblot))
•• InflammatroyInflammatroy infiltrateinfiltrate musclemuscle decreaseddecreased
•• No effect No effect onon CK CK oror functionfunction
•• DosingDosing needsneeds to to bebe optimizedoptimized furtherfurtherCirak et al, Lancet 2011, 378: 595‐605
Systemic trials MDEX/AVI
Annemieke Aartsma-Rus Cirak et al, Lancet 2011, 378: 595‐605
Planned/ongoing trials
Annemieke Aartsma-Rus
•• Exon 51 Exon 51 skippingskipping•• Non ambulant trial Non ambulant trial ongoingongoing USA (GSK/USA (GSK/ProsensaProsensa))•• DoseDose frequencyfrequency trial trial ongoingongoing (GSK/(GSK/ProsensaProsensa))•• ComparativeComparative dosedose trial trial plannedplanned (GSK/(GSK/ProsensaProsensa))•• PhasePhase 3 trial 3 trial ongoingongoing (GSK/(GSK/ProsensaProsensa))•• AVIAVI‐‐4658 4658 higherhigher dosedose startedstarted (AVI/NWH USA)(AVI/NWH USA)
•• Exon 44 Exon 44 skippingskipping PhasePhase I/II I/II ongoingongoing ((ProsensaProsensa))•• Plans Plans forfor exon 45 and 53 trials (exon 45 and 53 trials (ProsensaProsensa))•• OptimizationOptimization otherother exonsexons ongoingongoing (52 & 55) (52 & 55)